Literature DB >> 35767091

Less Than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis.

Damien Bouriez1, Caroline Gronnier1, Magalie Haissaguerre2, Antoine Tabarin2, Haythem Najah3.   

Abstract

BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1)-associated primary hyperparathyroidism (pHPT) is classically associated with an asymmetric and asynchronous parathyroid involvement. Subtotal parathyroidectomy (STP), which is currently the recommended surgical treatment, carries a high risk of permanent hypoparathyroidism. The results of less than subtotal parathyroidectomy (LSTP) are conflicting, and its place in this setting is still a matter of debate. The aim of this study was to identify the place of LSTP in the surgical management of patients with MEN-associated pHPT.
METHODS: A systematic literature review was conducted in accordance with PRISMA and MOOSE guidelines, for studies comparing STP and LSTP for MEN1-associated pHPT. The results of the two techniques, regarding permanent hypoparathyroidism, persistent hyperparathyroidism and recurrent hyperparathyroidism were computed using pairwise random-effect meta-analysis.
RESULTS: Twenty-five studies comparing STP and LSTP qualified for inclusion in the quantitative synthesis. In total, 947 patients with MEN1-associated pHPT were allocated to STP (n = 569) or LSTP (n = 378). LSTP reduces the risk of permanent hypoparathyroidism [odds ratio (OR) 0.29, confidence interval (CI) 95% 0.17-0.49)], but exposes to higher rates of persistent hyperparathyroidism [OR 4.60, 95% CI 2.66-7.97]. Rates of recurrent hyperparathyroidism were not significantly different between the two groups [OR 1.26, CI 95% 0.83-1.91].
CONCLUSIONS: LSTP should not be abandoned and should be considered as a suitable surgical option for selected patients with MEN1-associated pHPT. The increased risk of persistent hyperparathyroidism could improve with the emergence of more efficient preoperative localization imaging techniques and a more adequate patients selection.
© 2022. The Author(s) under exclusive licence to Société Internationale de Chirurgie.

Entities:  

Mesh:

Year:  2022        PMID: 35767091     DOI: 10.1007/s00268-022-06633-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.282


  45 in total

1.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Int J Surg       Date:  2010-02-18       Impact factor: 6.071

Review 2.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

Review 3.  Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review.

Authors:  Matthias Büttner; Thomas J Musholt; Susanne Singer
Journal:  Endocrine       Date:  2017-08-18       Impact factor: 3.633

Review 4.  The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review.

Authors:  Jennifer M J Schreinemakers; Carolina R C Pieterman; Anouk Scholten; Menno R Vriens; Gerlof D Valk; Inne H M Borel Rinkes
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

Review 5.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

Authors:  D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

Review 6.  The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1.

Authors:  S E Carty; A K Helm; J A Amico; M R Clarke; T P Foley; C G Watson; J J Mulvihill
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

7.  Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism.

Authors:  Trisha Dwight; Anne E Nelson; George Theodosopoulos; Anne Louise Richardson; Diana L Learoyd; Jeanette Philips; Leigh Delbridge; Jan Zedenius; Bin T Teh; Catharina Larsson; Deborah J Marsh; Bruce G Robinson
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

8.  Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.

Authors:  Jeffrey A Norton; David J Venzon; Marc J Berna; H R Alexander; Douglas L Fraker; Stephen K Libutti; Stephen J Marx; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

9.  Presentation of Hypoparathyroidism: Etiologies and Clinical Features.

Authors:  Dolores M Shoback; John P Bilezikian; Aline G Costa; David Dempster; Henning Dralle; Aliya A Khan; Munro Peacock; Marco Raffaelli; Barbara C Silva; Rajesh V Thakker; Tamara Vokes; Roger Bouillon
Journal:  J Clin Endocrinol Metab       Date:  2016-03-04       Impact factor: 5.958

10.  Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway.

Authors:  Marianne C Astor; Kristian Løvås; Aleksandra Debowska; Erik F Eriksen; Johan A Evang; Christian Fossum; Kristian J Fougner; Synnøve E Holte; Kari Lima; Ragnar B Moe; Anne Grethe Myhre; E Helen Kemp; Bjørn G Nedrebø; Johan Svartberg; Eystein S Husebye
Journal:  J Clin Endocrinol Metab       Date:  2016-05-17       Impact factor: 5.958

View more
  1 in total

1.  Invited Commentary: Less than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis.

Authors:  F Fausto Palazzo
Journal:  World J Surg       Date:  2022-08-30       Impact factor: 3.282

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.